318 Forum - Dr. John Vanchiere, professor of medicine and pediatrics, director of community testing and vaccinations and principal investigator for the Pfizer Vaccine Trial in north Louisiana at LSUHS, shares, "The CDC recommends that people ages 12 years and older receive one dose of the updated COVID-19 bivalent booster vaccine if it has been at least two months since their last vaccine dose."
The goal of LSUHS community vaccine sites is to provide every eligible citizen with access to the vaccine as soon as possible. LSUHS held the first large-scale COVID-19 vaccine clinic in Louisiana and has administered over 133,000 doses of the COVID-19 vaccine since November 2020.
The COVID-19 vaccine is currently unavailable at the LSU Health Shreveport North Campus site.
Please call 318-675-7166 with questions.
COVID-19 Vaccine Information (click a tab below)
Washington Examiner - The Biden administration's fall campaign to get people vaccinated with the omicron booster has been off to a slow start. Dr. John Vanchiere, director for community outreach for Center for Emerging Viral Threats at LSUHS, anticipates that more people will get the updated booster as it gets closer to Thanksgiving in preparation for traveling and visiting family.
NPR Red River Radio - Dr. Jeremy Kamil, LSUHS virologist, answers questions about the COVID-19 booster and when to get your flu shot.
Bossier Press-Tribune - The FDA-authorized bivalent COVID-19 vaccines, or updated boosters, are now available at LSUHS and include an mRNA component of the original strain to provide an immune response that is broadly protective against COVID-19.
The LSU Health Shreveport COVID-19 Strike Teams reached a major milestone today having administered just over 100,000 VACCINATIONS. Over 175 individuals have been a part of the LSUHS vaccine teams comprised of physicians, nurses, nursing, medical and allied health students, and the Louisiana National Guard.
KTBS3 - Dr. John Vanchiere, the lead investigator in the Pfizer vaccine study at LSUHS said, “We expect that to take at least four to six weeks of time. And Pfizer and Moderna are both starting additional enrollment in the pediatric studies in that 5- to 11-year-old age range, so that they can get more data under the research protocol to submit to the FDA when it’s appropriate.”
KTBS3 - Dr. John Vanchiere, an infectious disease and pediatrics specialist and the lead investigator on the Pfizer vaccine study at LSU Health Shreveport, shares "Demonstrating effectiveness that is preventing hospitalization and death or severe disease is very challenging in the pediatric population, because kids don't get generally very sick."
StatNews - By cutting how much the virus replicates — both through preventing infections and by shortening the infections that do occur — vaccines limit the likelihood of additional, more dangerous variants. Says Jeremy Kamil, a virologist at LSUHS, “The virus has to replicate in order to mutate, but each virus doesn’t get many lottery tickets in a vaccinated person who’s infected.”
BBC - Dr, Jeremy Kamil, a virologist at LSUHS, says "I would be delighted that a vaccine company overcame the immense challenges to make it work. But it's imperative that the efficacy data be vetted independently."
KEEL - Dr. John Vanchiere, LSUHS Pediatric and Infectious Disease Specialist, explains, "Booster shots are recommended for individuals who are moderate to severe immune-compromised. It's the same vaccine, just like the second dose, you're going to get a third dose of the same thing."
Heavy.com - Dr. Jeremy Kamil, Associate Professor of Microbiology and Immunology at LSUHS leads COVID-19 sequencing at the institution shared that he believes a doomsday variant is extremely unlikely and that people should be talking instead about the importance of getting vaccinated because variants can develop when large numbers of people do not.
Dr. John Vanchiere, Professor of Pediatrics and Infectious Disease at LSUHS served as was one of eight clinical leaders in Louisiana invited to participate in The Louisiana Community Engagement Alliance Against Covid-19 Disparities (LA-CEAL) Town Hall meeting which was designed to provided updated information on COVID-19.
New York Times - Facing deep mistrust stoked by rampant conspiracy theories, local health officials are fighting for influence when the only sure strategy for beating back the virus is getting more people vaccinated. “It’s a lot of small battles in different places,” Dr. John Vanchiere said, “and every battle is going to be different.”
Boston Globe - Dr. Jeremy Kamil, an associate professor of microbiology and immunology at LSUHS, oversees a team of scientists reading the genomes of positive virus samples each week. A run of samples this week found the number of cases involving the delta variant had exploded. Dr. John Vanchiere, a professor of infectious disease at LSUHS said a growing public awareness of local delta cases was one reason his team was now vaccinating twice as many people as a month ago — as many as 100 a day.
Boston 25 News - Dr. Jeremy Kamil, an associate professor of microbiology and immunology at LSU Health in Shreveport, Louisiana, calls the two-dose data very clear and very strong. “You can control your behavior and go back and get that second shot and do your part to protect our community and to protect our country from the pandemic having another big wave here."
BBC World - Even with 166 examples of Delta plus shared on GISAID, "we don't have much reason to believe this is any more dangerous than the original Delta," according to Dr Jeremy Kamil, a virologist at LSU Health Shreveport. "Delta plus might have a slight advantage at infecting and spreading between people previously infected earlier or who have weak or incomplete vaccine immunity."
NOLA.com - “This virus can get past the defenses that our bodies made against earlier pandemic viruses,” said Jeremy Kamil, a virologist who has been sequencing variants at LSU Health Shreveport. Being infected last summer will not necessarily protect someone from being infected by the delta variant.
KSLA 12 - Across Louisiana, more than 3 million doses of the vaccine have been placed in arms, while 1.4 million Louisianans are fully vaccinated — about 32% of the state. “The faster we can vaccinate ... the more difficult it is for these variants to emerge across the world, and we are seeing it,” LSUHS Dr. John Vanchiere said.
New York Times - The split is particularly stark in Britain, which is facing the spread of a new variant, while America has essentially lifted all rules for people who are vaccinated. “Globally, it’s a nightmare, because most of the world is still not vaccinated,” said Jeremy Kamil, a virologist at Louisiana State University Health Shreveport. “It raises the stakes.”
The74Million - “Until you get upwards of 80 percent of children vaccinated, you’re going to have a hard time going back to pre-pandemic practices without some risk of illness and death,” Jeremy Kamil, associate professor of microbiology and immunology at Louisiana State University Health Shreveport, told The 74.
KTBS - Dr. John Vanchiere, lead investigator on the Pfizer vaccine study at LSUHS said, “The vaccine is effective at several things. Number one, reducing people from getting sick from COVID and spreading it to other people. Big time important is that vaccination reduces hospitalization and death.”
CNN News 18 - India recorded on Monday 3,52,991 new Covid-19 cases and 2,812 deaths in the last 24 hours. The country saw 22.5 lakh new infections in the last one week, the highest ever the world has seen, pushing India’s health infrastructure to a brim.
“LSUHS is adjusting our strategy to accommodate more folks,” Dr. John Vanchiere said. “I would like to see longer lines and more people there getting vaccinated. And we have (the) capacity to vaccinate more than 2,000 or 2,500 people per day.”
NBC CT - LSU Health Shreveport Virologist Jeremy Kamil told NBC Connecticut Investigates that halting their spread will require other measures. Kamil was among a team of researchers that discovered seven new COVID-19 strains, known as "variants," aside from the variants first identified in the UK, South Africa, and Brazil.
We are proud to announce that on February 24, 2021, 2:00 PM – 3:30 PM EST Dr. G.E. Ghali, Chancellor for LSU Health Shreveport has been invited to be part of a panel of four people on one of the Town Hall Sessions on the topic of Building Bridges between Public Health and Healthcare Systems to Ensure Equitable Vaccination.
Governor John Bel Edwards visited Louisiana’s first mass community vaccine clinic to see firsthand just how well the community effort involving LSU Health Shreveport faculty, students and staff, Region 7 Office of Public Health, Louisiana National Guard, BPCC nursing students, CHRISTUS Shreveport-Bossier Health System and Willis-Knighton Health System is working
Shreveport Times - Dr. John Vanchiere, professor and chief of pediatric infectious diseases at LSUHS, talked about the benefits of getting the vaccine and its safety. “We know that early on when people get infected with COVID-19, most people have no symptoms at all and that is one of the very critical features of this type of infection compared to influenza."
KTBS3 - While most Americans are still waiting to get the COVID-19 vaccine, some moms-to-be are worried about possible side effects to their unborn children.
KTBS 3 - “The quicker that people get vaccinated, the less chance of any virus being around and given the opportunity to mutate,” Dr. Ghali, LSU Health Shreveport Chancellor explained. “The longer a virus is around, the longer they're going to be able to mutate. It's a natural course in the development of the virus.”
This week LSU Health Shreveport took a historic step towards stopping the spread of the coronavirus. In addition to continuously testing for COVID-19, the Emerging Viral Threat Lab has now organized the distribution of the vaccine to individuals age 70 and up. On the first day of testing, over 1100 seniors were able to get the vaccine from the safety of their vehicles.
As it relates to COVID, each of us will make a choice about the vaccine. I choose to be vaccinated because I have seen the complications of COVID close up and have great faith in the scientific trials supporting this vaccine.
KSLA 12 - Dr. Robert Rhoads, professor and emeritus chairman of the Department of Biochemistry and Molecular Biology at LSU Health Shreveport, developed key components of the mRNA over years of work. The vaccine uses messenger RNA, or mRNA, which essentially provides instructions to the body on how to fight the novel coronavirus.
KSLA 12 - “It is gratifying to see LSU Health Shreveport’s contributions to the Pfizer-BioNTech vaccine through licensing of a LSUHS patent to BioNTech for mRNA-stabilizing cap analogs and in serving as the only north Louisiana vaccine trial site. Additionally our numerous COVID-19 clinical trials are providing access to novel therapies reflecting the benefit of having an academic medical center in our community,” shared Dr. G.E. Ghali, Chancellor of LSU Health Shreveport.
LSUHS is expanding enrollment in the Pfizer-sponsored COVID-19 vaccine study for the next two weeks to include individuals ages 16-18 and those older than 85 years of age. Those interested in participating in this important vaccine trial should sign up as quickly as possible.
KTBS 3 - LSU Health Shreveport announced this week that it is participating in the Pfizer COVID-19 vaccine study and is currently enrolling people to participate.